查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1555474

流感藥物市場，按藥物類型、按流感類型、按年齡層、按給藥途徑、按配銷通路和按地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Influenza Medications Market, By Drug Type, By Influenza Type, By Age Group, By Route of Administration, By Distribution Channel and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 399 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年流感藥物市場規模為9.3243億美元，2024年至2032年複合年成長率為7.2%。

流感藥市場-市場動態

流感發病率的增加預計將推動市場的成長

流感是一種季節性復發的疾病，每年都會在全球不同地區爆發。流感季節期間發病率較高，導致對藥物干預措施的需求增加。此外，零星的流感大流行或流行病會大大增加流感的發生率，導致抗病毒治療和預防策略的需求激增。美國疾病管制與預防中心 (CDC) 估計，本季流感導致至少 3,500 萬例、40 萬人住院治療和 25,000 人死亡。此外，抗病毒藥物和綜合治療方法開發的進步為市場帶來了巨大的成長機會。儘管如此，與新藥相關的高成本可能會對市場擴張帶來挑戰。

流感藥物市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 7.2% 左右的複合年成長率成長

根據藥物類型細分，預計抗病毒藥物將在 2023 年呈現最大市場佔有率

根據流感類型細分，甲型流感是 2023 年的主要類型

依年齡層別分類，2023年成人為主導類型

根據給藥途徑細分，2023年口服是領先類型

從配銷通路細分來看，醫院藥局是2023年的主導類型

按地區分類，北美是 2023 年的主要收入來源

流感藥物市場-細分分析：

全球流感藥物市場根據藥物類型、流感類型、年齡層、給藥途徑、配銷通路和地區進行細分。

依藥物類型，市場分為三類：抗病毒藥物、抗組織胺、鎮痛解熱藥。抗病毒藥物在市場上佔據主導地位。這些藥物的配方是為了減輕流感症狀的強度和持續時間，在某些情況下，它們還可以避免併發症。

根據流感類型，市場分為兩個部分：甲型流感和乙型流感。它因其在引發每年流感流行中的作用而受到認可，並且由於其快速突變能力而具有導致大流行的能力。

市場依年齡層分為三個部分：成人、兒童和老年。成人細分市場佔據主導地位。鑑於成年人經常經歷季節性流感，且疾病的嚴重程度受到年齡、潛在健康狀況和疫苗接種史等因素的影響，因此以成人為重點的流感藥物市場是關鍵部分。

根據給藥途徑，市場分為三類：口服、吸入和靜脈注射。口服品類在市場上佔主導地位。口服抗病毒藥物通常是對抗流感的主要選擇，特別是在治療輕度至中度病例時。

根據配銷通路，市場分為三個不同的類別：醫院藥房、零售藥房和線上藥房。醫院藥房佔據市場主導地位。醫院需要有效的抗病毒治療來照顧嚴重後果風險增加的患者，包括老年人、已有健康狀況的人和免疫系統受損的人。

流感藥物市場 - 地理洞察

市場地域廣闊，涵蓋北美、拉丁美洲、歐洲、亞太地區、中東和非洲。這些領域根據對商業活動做出貢獻的國家進一步分類。在先進藥物療法的採用增加和醫療保健支出增加的推動下，北美引領市場。北美，特別是美國的監管框架有利於新流感治療方法的快速批准和實施。這包括獲得其他地區可能尚無法獲得的創新療法。根據美國國家癌症中心報告，2022年，共有37種新藥（稱為新藥）在美國首次獲得批准。健康統計。由於意識的提高和早期診斷，歐洲成為第二大市場擴張地區。

流感藥物市場-競爭格局：

流感藥物市場表現出高度的競爭力，其特點是許多製藥公司努力爭取更大的佔有率，特別是在抗病毒領域。本次競賽的一個重要焦點在於採用獨特作用機制的新型抗病毒藥物的創新。那些分配資源用於研發以製定能夠克服抗藥性並提供增強功效或便利的先進流感療法的公司正在策略性地定位自己，以抓住未來的市場機會。此外，這些公司正在努力在新興市場建立強大的影響力，這些市場人口眾多且流感發病率不斷上升，帶來了巨大的銷售潛力。公司之間也共同努力提高人們對早期抗病毒干預優勢的認知，特別是在流感季節。

最新進展：

2024 年 5 月，阿斯特捷利康將於 5 月在加州聖地牙哥舉行的美國胸腔科學會 (ATS) 國際會議上展示其著名的吸入、生物和早期呼吸產品組合的新臨床和現實世界發現2024 年5月17 日至5 月22 日。的未滿足需求，以及患有其他慢性呼吸道疾病。

2023 年 10 月，賽諾菲和 Teva Pharmaceutical Industries Ltd. 的美國子公司 Teva Pharmaceuticals 宣佈建立合作夥伴關係，旨在共同開發和共同商業化資產 TEV'574。該資產目前正在進行 2b 期臨床試驗，用於治療潰瘍性結腸炎和克隆氏症，這兩種疾病都是發炎性腸道疾病。

目錄

第1章：流感藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類型分類的流感藥物市場片段
    • 按流感類型分類的流感藥物市場片段
    • 按年齡分類的流感藥物市場片段
    • 按給藥途徑分類的流感藥物市場摘要
    • 按配銷通路分類的流感藥物市場片段
    • 按國家/地區分類的流感藥物市場摘要
    • 按地區分類的流感藥物市場片段
  • 競爭洞察

第 3 章：流感藥物主要市場趨勢

  • 流感藥物市場促進因素
    • 市場促進因素的影響分析
  • 流感藥物市場限制
    • 市場限制影響分析
  • 流感藥物市場機會
  • 流感藥物市場未來趨勢

第 4 章：流感藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：流感藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：流感藥物市場格局

  • 2023 年流感藥物市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：流感藥物市場 - 依藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 抗病毒藥物
      • 單一抗病毒藥物
      • 聯合抗病毒藥物
    • 抗組織胺藥
    • 止痛藥
    • 退燒藥

第 8 章：流感藥物市場 - 按流感類型

  • 概述
    • 按流感類型分類的細分市場佔有率分析
    • 甲型流感
    • 乙型流感

第 9 章：流感藥物市場 - 按年齡層

  • 概述
    • 按年齡層別分類的細分市場佔有率分析
    • 成年人
    • 兒科
    • 老年科

第 10 章：流感藥物市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 吸入
    • 靜脈

第 11 章：流感藥物市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 12 章：流感藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美流感藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類型）
    • 北美市場規模與預測（按流感類型）
    • 北美市場規模和預測（按年齡層）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲流感藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類型）
    • 歐洲市場規模與預測（按流感類型）
    • 歐洲市場規模和預測（按年齡層）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區流感藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類型）
    • 亞太地區市場規模與預測（按流感類型）
    • 亞太地區市場規模與預測（依年齡層）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲流感藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類型）
    • 拉丁美洲市場規模與預測（按流感類型）
    • 拉丁美洲市場規模與預測（按年齡層）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲流感藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類型）
    • 中東和非洲市場規模及預測（按流感類型）
    • 中東和非洲市場規模及預測（按年齡層）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 13 章：主要供應商分析 - 流感藥物產業

  • 競爭儀表板
  • 公司簡介
    • AstraZeneca plc
    • Teva Pharmaceutical Industries Ltd
    • BioCryst Pharmaceuticals, Inc.
    • Sanofi
    • Daiichi Sankyo Company
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • NATCO Pharma Limited
    • GlaxoSmithKline plc
    • Lupin
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3636

REPORT HIGHLIGHT

Influenza Medications Market size was valued at USD 932.43 million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

Medications for influenza are utilized to either treat or prevent infections caused by the flu. Antiviral drugs that target influenza viruses serve as a crucial complement to the influenza vaccine in managing the disease. These antiviral agents function by hindering the replication of the influenza virus, which in turn alleviates the severity and shortens the duration of symptoms. Their efficacy is maximized when administered promptly, preferably within 48 hours of the onset of symptoms. Thus, influenza medications play a vital role in alleviating flu symptoms and mitigating the overall effects of the infection.

Influenza Medications Market- Market Dynamics

The increasing incidence of influenza is expected to drive the growth of the market

Influenza is a recurring illness that manifests seasonally, resulting in annual outbreaks across various regions globally. The heightened occurrence during the flu season leads to an increased demand for pharmaceutical interventions. Additionally, sporadic flu pandemics or epidemics can considerably elevate the incidence of influenza, resulting in surges in the need for antiviral therapies and preventive strategies. The Centers for Disease Control and Prevention (CDC) estimates that this season has witnessed at least 35 million cases, 400,000 hospitalizations, and 25,000 fatalities attributed to the flu. Moreover, advancements in the development of antiviral medications and integrated treatment methodologies present significant growth opportunities for the market. Nonetheless, the high costs associated with novel medications may pose challenges to market expansion.

Influenza Medications Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Drug Type segmentation, Antiviral drugs were predicted to show maximum market share in the year 2023

Based on Influenza Type segmentation, Influenza A was the leading type in 2023

Based on Age Group segmentation, Adults were the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution Channel segmentation, Hospital pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Influenza Medications Market- Segmentation Analysis:

The Global Influenza Medications Market is segmented based on Drug Type, Influenza Type, Age Group, Route of Administration, Distribution Channel, and Region.

The market is segmented into three classifications according to Drug Type: Antiviral drugs, Antihistamines, and Analgesics and Antipyretics. Antiviral drugs hold a dominant position in the market. These drugs are formulated to alleviate the intensity and length of flu symptoms, and in certain instances, they may also avert complications.

The market is classified into two segments according to the influenza type: Influenza A and Influenza B. Influenza A holds a predominant position in the market. It is recognized for its role in triggering yearly flu epidemics and possesses the capacity to result in pandemics owing to its rapid mutation capabilities.

The market is classified into three segments according to age groups: Adults, Pediatric, and Geriatric. The Adult segment dominates the market. The Influenza Medications Market focused on adults represents a crucial segment, given that adults frequently experience seasonal influenza, with the severity of the illness influenced by factors such as age, underlying health conditions, and vaccination history.

The market is segmented into three categories according to the route of administration: Oral, Inhaled, and Intravenous. The Oral category holds a dominant position in the market. Oral antiviral medications are frequently the primary option for combating influenza, especially in the treatment of mild to moderate cases.

The market is segmented into three distinct categories according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Hospital pharmacies dominate the market. Hospitals necessitate efficient antiviral treatments to care for patients who are at an increased risk of severe outcomes, including the elderly, individuals with pre-existing health conditions, and those with compromised immune systems.

Influenza Medications Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads the market, driven by an increase in the adoption of advanced drug therapies and a rise in healthcare spending. The regulatory framework in North America, especially in the United States, facilitates the expedited approval and implementation of new influenza treatments. This includes access to innovative therapies that may not yet be accessible in other regions. In 2022, a total of 37 new drugs, referred to as novel drugs, were approved for the first time in the U.S. Additionally, previously approved drugs were authorized for new applications, including new indications and patient demographics, as reported by the National Center for Health Statistics. Europe positions as the second largest region for market expansion, attributed to increasing awareness and early diagnosis.

Influenza Medications Market- Competitive Landscape:

The Influenza Medications Market exhibits a high level of competitiveness, characterized by numerous pharmaceutical firms striving to secure a larger share, especially within the antiviral sector. A significant focus of this competition lies in the innovation of new antiviral medications that employ unique mechanisms of action. Firms that allocate resources towards research and development to formulate advanced influenza therapies capable of overcoming resistance and providing enhanced efficacy or convenience are strategically positioning themselves to seize future market opportunities. Additionally, these companies are working to establish a robust presence in emerging markets, where a substantial population and a rising incidence of influenza present considerable sales potential. There is also a concerted effort among companies to promote awareness regarding the advantages of early antiviral intervention, particularly during the flu season.

Recent Developments:

In May 2024, AstraZeneca is set to present new clinical and real-world findings from its prominent inhaled, biologic, and early-stage respiratory portfolio at the American Thoracic Society (ATS) International Conference, taking place in San Diego, CA, from May 17 to May 22, 2024. The company will unveil 59 abstracts, which include 12 late-breaking posters, concentrating on the unmet needs associated with chronic obstructive pulmonary disease (COPD), severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA), along with other chronic respiratory conditions.

In October 2023, Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced a partnership aimed at the co-development and co-commercialization of the asset TEV'574. This asset is presently undergoing Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, both of which are forms of inflammatory bowel disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFLUENZA MEDICATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd
  • BioCryst Pharmaceuticals, Inc.
  • Sanofi
  • Daiichi Sankyo Company
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • NATCO Pharma Limited
  • GlaxoSmithKline plc
  • Lupin
  • Others

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antiviral Drugs
  • Single Antiviral Drugs
  • Combination Antiviral Drugs
  • Antihistamines
  • Analgesics
  • Antipyretics

GLOBAL INFLUENZA MEDICATIONS MARKET, BY INFLUENZA TYPE- MARKET ANALYSIS, 2019 - 2032

  • Influenza A
  • Influenza B

GLOBAL INFLUENZA MEDICATIONS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Adults
  • Pediatric
  • Geriatric

GLOBAL INFLUENZA MEDICATIONS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Inhaled
  • Intravenous

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFLUENZA MEDICATIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Influenza Medications Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Influenza Medications Market Snippet by Drug Type
    • 2.1.2. Influenza Medications Market Snippet by Influenza Type
    • 2.1.3. Influenza Medications Market Snippet by Age Group
    • 2.1.4. Influenza Medications Market Snippet by Route of Administration
    • 2.1.5. Influenza Medications Market Snippet by Distribution Channel
    • 2.1.6. Influenza Medications Market Snippet by Country
    • 2.1.7. Influenza Medications Market Snippet by Region
  • 2.2. Competitive Insights

3. Influenza Medications Key Market Trends

  • 3.1. Influenza Medications Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Influenza Medications Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Influenza Medications Market Opportunities
  • 3.4. Influenza Medications Market Future Trends

4. Influenza Medications Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Influenza Medications Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Influenza Medications Market Landscape

  • 6.1. Influenza Medications Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Influenza Medications Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Antiviral Drugs
      • 7.1.2.1. Single Antiviral Drugs
      • 7.1.2.2. Combination Antiviral Drugs
    • 7.1.3. Antihistamines
    • 7.1.4. Analgesics
    • 7.1.5. Antipyretics

8. Influenza Medications Market - By Influenza Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Influenza Type, 2023 & 2032 (%)
    • 8.1.2. Influenza A
    • 8.1.3. Influenza B

9. Influenza Medications Market - By Age Group

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Age Group, 2023 & 2032 (%)
    • 9.1.2. Adults
    • 9.1.3. Pediatric
    • 9.1.4. Geriatric

10. Influenza Medications Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 10.1.2. Oral
    • 10.1.3. Inhaled
    • 10.1.4. Intravenous

11. Influenza Medications Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital Pharmacies
    • 11.1.3. Retail Pharmacies
    • 11.1.4. Online Pharmacies

12. Influenza Medications Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Influenza Medications Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Influenza Medications Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Influenza Medications Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Influenza Medications Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Influenza Medications Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Influenza Medications Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. AstraZeneca plc
    • 13.2.2. Teva Pharmaceutical Industries Ltd
    • 13.2.3. BioCryst Pharmaceuticals, Inc.
    • 13.2.4. Sanofi
    • 13.2.5. Daiichi Sankyo Company
    • 13.2.6. Novartis AG
    • 13.2.7. F. Hoffmann-La Roche AG
    • 13.2.8. NATCO Pharma Limited
    • 13.2.9. GlaxoSmithKline plc
    • 13.2.10. Lupin
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us